Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Social care data in the UK; current landscape, challenges, and future recommendations36
How to create value with constrained budgets in oncological care? A narrative review23
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States21
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment19
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology18
Indication-based pricing of the pharmaceuticals in Croatia: case-study18
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia17
Adherence to augmentation therapy for the treatment of major depressive disorder16
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis13
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study13
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency12
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data12
The role of insurance policies in the drug pricing landscape12
0.052720069885254